The COMMD1 protein, implicated in copper homeostasis, is found to regulate endosomal sorting of the copper transporter ATP7A through a novel protein complex containing CCDC22, CCDC93, and C16orf62, which link COMMD1 to the WASH complex.
Retromer is a membrane coat complex that is recruited to endosomes by the small GTPase Rab7 and sorting nexin 3. The timing of this interaction and consequent endosomal dynamics are thought to be regulated by the guanine nucleotide cycle of Rab7. Here we demonstrate that TBC1d5, a GTPase-activating protein (GAP) for Rab7, is a high-affinity ligand of the retromer cargo selective complex VPS26/VPS29/VPS35. The crystal structure of the TBC1d5 GAP domain bound to VPS29 and complementary biochemical and cellular data show that a loop from TBC1d5 binds to a conserved hydrophobic pocket on VPS29 opposite the VPS29–VPS35 interface. Additional data suggest that a distinct loop of the GAP domain may contact VPS35. Loss of TBC1d5 causes defective retromer-dependent trafficking of receptors. Our findings illustrate how retromer recruits a GAP, which is likely to be involved in the timing of Rab7 inactivation leading to membrane uncoating, with important consequences for receptor trafficking.
While TRAIL is a promising anticancer agent due to its ability to selectively induce
apoptosis in neoplastic cells, many tumors, including pancreatic ductal adenocarcinoma
(PDA), display intrinsic resistance, highlighting the need for TRAIL-sensitizing agents.
Here we report that TRAIL-induced apoptosis in PDA cell lines is enhanced by
pharmacological inhibition of glycogen synthase kinase-3 (GSK-3) or by shRNA-mediated
depletion of either GSK-3α or GSK-3β. In contrast, depletion
of GSK-3β, but not GSK-3α, sensitized PDA cell lines to
TNFα-induced cell death. Further experiments demonstrated that
TNFα-stimulated IκBα phosphorylation and
degradation as well as p65 nuclear translocation were normal in
GSK-3β-deficient MEFs. Nonetheless, inhibition of GSK-3β
function in MEFs or PDA cell lines impaired the expression of the NF-κB
target genes Bcl-xL and cIAP2, but not IκBα. Significantly,
the expression of Bcl-xL and cIAP2 could be reestablished by expression of
GSK-3β targeted to the nucleus but not GSK-3β targeted to
the cytoplasm, suggesting that GSK-3β regulates NF-κB
function within the nucleus. Consistent with this notion, chromatin immunoprecipitation
demonstrated that GSK-3 inhibition resulted in either decreased p65 binding to the
promoter of BIR3, which encodes cIAP2, or increased p50 binding as well as
recruitment of SIRT1 and HDAC3 to the promoter of BCL2L1, which encodes Bcl-xL.
Importantly, depletion of Bcl-xL but not cIAP2, mimicked the sensitizing effect of GSK-3
inhibition on TRAIL-induced apoptosis, whereas Bcl-xL overexpression ameliorated the
sensitization by GSK-3 inhibition. These results not only suggest that
GSK-3β overexpression and nuclear localization contribute to TNFα
and TRAIL resistance via anti-apoptotic NF-κB genes such as Bcl-xL, but
also provide a rationale for further exploration of GSK-3 inhibitors combined with TRAIL
for the treatment of PDA.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.